{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:28:25Z","timestamp":1775096905284,"version":"3.50.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multi-target peptide therapeutics targeting glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR) represent a promising approach for treating diabetes and obesity. Triple agonist peptides demonstrate promising therapeutic potential compared to single-target approaches, yet rational design remains computationally challenging due to complex sequence-structure activity relationships. Existing methods, primarily based on convolutional neural networks, impose limitations including fixed sequence lengths and inadequate representation of molecular topology. Graph Attention Networks (GAT) offer advantages in capturing molecular structures and variable-length peptide sequences while providing interpretable insights into receptor-specific binding determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dataset of 234 peptide sequences with experimentally determined binding affinities was compiled from multiple sources. Peptides were represented as molecular graphs with seven-dimensional node features encoding physicochemical properties and positional information. The GAT architecture employed a shared encoder with task-specific prediction heads, implementing transfer learning to address limited GIPR training data. Performance was evaluated using 5-fold cross-validation and independent validation on 24 literature-derived sequences. A genetic algorithm framework was developed for peptide sequence optimization, incorporating multi objective fitness evaluation based on predicted binding affinity, biological plausibility, and sequence novelty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cross-validation demonstrated robust GAT performance across all receptors, with GCGR achieving high accuracy (AUC ROC: 0.915 \u00b1 0.050), followed by GLP1R (AUC-ROC: 0.853 \u00b1 0.059), and GIPR showing acceptable performance despite limited data (AUC-ROC: 0.907 \u00b1 0.083). Comparative analysis revealed receptor-specific advantages: GAT significantly outperformed CNN for GCGR prediction (RMSE: 0.942 vs. 1.209, p = 0.0013), while CNN maintained superior GLP1R performance (RMSE: 0.552 vs. 0.723). Genetic algorithm optimization measurable improvement over baseline, with 4.0% fitness Enhancement and generation of 20 candidates exhibiting mean binding probabilities exceeding 0.5 across all targets. The GAT-based framework provides a computational approach in computational peptide design, demonstrating receptor-specific advantages and robust optimization capabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Genetic algorithm optimization enables systematic exploration of sequence space within existing agonist scaffolds while maintaining biological constraints. This approach provides a rational framework for prioritizing experimental validation efforts in triple agonist development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2025.1687617","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:26:11Z","timestamp":1763360771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease"],"prefix":"10.3389","volume":"5","author":[{"given":"Anthony","family":"Wong","sequence":"first","affiliation":[]},{"given":"Sanskruthi","family":"Guduri","sequence":"additional","affiliation":[]},{"given":"TsungYen","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Kunal","family":"Patel","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/bph.15538","article-title":"The concise guide to pharmacology 2021\/22: g protein-coupled receptors","volume":"178","author":"Alexander","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/met.2008.0070","article-title":"Health care utilization and costs by metabolic syndrome risk factors","volume":"7","author":"Boudreau","year":"2009","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.peptides.2017.12.021","article-title":"Gut hormone polyagonists for the treatment of type 2 diabetes","volume":"100","author":"Brandt","year":"2018","journal-title":"Peptides"},{"key":"B6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2337\/diab.6.3.234","article-title":"The amino acid sequence of glucagon","volume":"6","author":"Bromer","year":"1957","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1021\/acs.jmedchem.1c01456","article-title":"The design and optimization of monomeric multitarget peptides for the treatment of multifactorial diseases","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1038\/s41467-024-49215-y","article-title":"Rule-based omics mining reveals antimicrobial macrocyclic peptides against drug-resistant clinical isolates","volume":"15","author":"Cheng","year":"2024","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","article-title":"Biopython: freely available python tools for computational molecular biology and bioinformatics","volume":"25","author":"Cock","year":"2009","journal-title":"Bioinformatics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1021\/acs.jmedchem.8b00292","article-title":"Dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists specifically optimized for multidose formulations","volume":"61","author":"Evers","year":"2018","journal-title":"J. Med. Chem."},{"key":"B14","article-title":"Fast graph representation learning with PyTorch geometric","author":"Fey","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102129","DOI":"10.1016\/j.molmet.2025.102129","article-title":"A once-daily GLP-1\/GIP\/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans","volume":"96","author":"Finan","year":"2025","journal-title":"Mol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/s0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"B19","first-page":"1416","article-title":"Large-scale learnable graph convolutional networks","volume-title":"Proceedings of the 24th ACM SIGKDD international conference on knowledge discovery and data mining","author":"Gao","year":"2018"},{"key":"B20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/ph15050646","article-title":"Drug design by pharmacophore and virtual screening approach","volume":"15","author":"Giordano","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/protein\/4.2.155","article-title":"Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence","volume":"4","author":"Guruprasad","year":"1990","journal-title":"Protein Eng."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9955","DOI":"10.1021\/jm4017448","article-title":"Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human Primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/aabc.s70333","article-title":"Molecular dynamics simulations: advances and applications","volume":"8","author":"Hospital","year":"2015","journal-title":"Adv. Appl. Bioinform Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/nejmoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/j.bmc.2017.10.047","article-title":"Optimization of peptide-based polyagonists for treatment of diabetes and obesity","volume":"26","author":"Knerr","year":"2018","journal-title":"Bioorg Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1609.02907","article-title":"Semi-supervised classification with graph convolutional networks","author":"Kipf","year":"2016","journal-title":"arXiv Prepr. arXiv:1609.02907"},{"key":"B28","doi-asserted-by":"publisher","first-page":"170225","DOI":"10.1016\/j.peptides.2019.170225","article-title":"Selection and progression of unimolecular agonists at the GIP, GLP-1 and glucagon receptors as drug candidates","volume":"125","author":"Knerr","year":"2020","journal-title":"Peptides"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in Obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J. Med. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0022-2836(82)90515-0","article-title":"A simple method for displaying the hydropathic character of a protein","volume":"157","author":"Kyte","year":"1982","journal-title":"J. Mol. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/postmj\/qgad008","article-title":"Prevalence of metabolic syndrome in the United States national health and nutrition examination survey 2011\u201318","volume":"99","author":"Liang","year":"2023","journal-title":"Postgrad. Med. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11218","DOI":"10.1109\/TNNLS.2023.3250324","article-title":"Meta learning with graph attention networks for low-data drug discovery","volume":"35","author":"Lv","year":"2024","journal-title":"IEEE Trans. Neural Netw. Learn Syst."},{"key":"B35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1021\/jm900752a","article-title":"Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity","volume":"52","author":"Mapelli","year":"2009","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1021\/jm8008579","article-title":"Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1","volume":"51","author":"Meng","year":"2008","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1021\/jm701522b","article-title":"Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity","volume":"51","author":"Miranda","year":"2008","journal-title":"J. Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0014-5793(84)81114-x","article-title":"The isolation and sequencing of human gastric inhibitory peptide (GIP)","volume":"172","author":"Moody","year":"1984","journal-title":"FEBS Lett."},{"key":"B42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fendo.2012.00141","article-title":"Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction","volume":"3","author":"Moon","year":"2012","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"10106","DOI":"10.1016\/j.bmc.2008.10.006","article-title":"Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1","volume":"16","author":"Murage","year":"2008","journal-title":"Bioorg Med. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12826","DOI":"10.1016\/s0021-9258(18)51561-1","article-title":"Complete sequences of glucagon-like peptide-1 from human and pig small intestine","volume":"264","author":"Orskov","year":"1989","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejmech.2016.10.044","article-title":"Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling","volume":"127","author":"Plisson","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41557-024-01532-x","article-title":"Machine learning designs new GCGR\/GLP-1R dual agonists with enhanced biological potency","volume":"16","author":"Puszkarska","year":"2024","journal-title":"Nat. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.aaz5346","article-title":"Structural basis of Gs and Gi recognition by the human glucagon receptor","volume":"367","author":"Qiao","year":"2020","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.copbio.2006.10.002","article-title":"Therapeutic peptides: technological advances driving peptides into development","volume":"17","author":"Sato","year":"2006","journal-title":"Curr. Opin. Biotechnol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-021-00631-w","article-title":"A new GLP1, GIP and glucagon receptor triagonist","volume":"18","author":"Starling","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1124\/pr.110.003145","article-title":"Modulation of peripheral sensory neurons by the immune system: implications for pain therapy","volume":"63","author":"Stein","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cels.2020.08.016","article-title":"Fast and flexible protein design using deep graph neural networks","volume":"11","author":"Strokach","year":"2020","journal-title":"Cell Syst."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1706.03762","article-title":"Attention is all you need","volume":"30","author":"Vaswani","year":"2017","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1710.10903","article-title":"Graph attention networks","author":"Veli\u010dkovi\u0107","year":"2017","journal-title":"arXiv Prepr. arXiv:1710.10903"},{"key":"B57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2337\/cd25-0018","article-title":"Triple agonist therapy: a new frontier in treating type 2 diabetes and obesity","volume":"43","author":"Whitley","year":"2025","journal-title":"Clin. Diabetes"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1021\/acs.jmedchem.5b01909","article-title":"Synthesis and pharmacological characterization of novel glucagon-like Peptide-2 (GLP-2) analogues with low systemic clearance","volume":"59","author":"Wi\u015bniewski","year":"2016","journal-title":"J. Med. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1109\/tnnls.2020.2978386","article-title":"A comprehensive survey on graph neural networks","volume":"32","author":"Wu","year":"2020","journal-title":"IEEE Trans. Neural Netw. Learn Syst."},{"key":"B63","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1021\/acs.jmedchem.9b00959","article-title":"Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism","volume":"63","author":"Xiong","year":"2020","journal-title":"J. Med. Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like Peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41592-019-0496-6","article-title":"Machine-learning-guided directed evolution for protein engineering","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Methods"},{"key":"B66","doi-asserted-by":"publisher","first-page":"102327","DOI":"10.1016\/j.sbi.2021.102327","article-title":"Graph neural network approaches for drug-target interactions","volume":"73","author":"Zhang","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"118024","DOI":"10.1016\/j.ejmech.2025.118024","article-title":"Design, synthesis, and structure-activity relationship study of novel GLP-1\/GIP\/GCG triple receptor agonists","volume":"298","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metab."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1687617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:26:13Z","timestamp":1763360773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1687617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":69,"alternative-id":["10.3389\/fbinf.2025.1687617"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2025.1687617","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1687617"}}